Sarepta Therapeutics Announces Pricing of $125 Million Public

Sarepta Therapeutics Announces Pricing of $125 Million Public
Offering of Common Stock 
CAMBRIDGE, MA -- (Marketwire) -- 12/13/12 --  Sarepta Therapeutics,
Inc. (NASDAQ: SRPT) today announced that it has priced an
underwritten public offering of an aggregate of 4,950,495 shares of
its common stock at a price to the public of $25.25 per share. In
addition, Sarepta has granted the underwriters a 30-day option to
purchase up to an additional 742,574 shares of common stock on the
same terms and conditions, solely to cover over-allotments, if any.
Sarepta anticipates the aggregate net proceeds from the offering will
be approximately $118.2 million, after deducting the underwriting
discount and estimated offering expenses payable by Sarepta, but
excluding any exercise of the underwriters' over-allotment option.
The offering is expected to close on or about December 18, 2012,
subject to customary closing conditions.  
Lazard Capital Markets LLC is acting as the sole book-running manager
of the offering. Cowen and Company LLC is acting as the co-lead
manager, and JMP Securities LLC, Wedbush PacGrow Life Sciences and
Canaccord Genuity are each acting as co-managers for the offering.  
Sarepta intends to use the net proceeds from the offering for general
corporate purposes, including the continued development of eteplirsen
and other product candidates. 
The shares described above will be issued pursuant to a prospectus
supplement filed as part of a shelf registration statement on Form
S-3 ASR previously filed with and declared effective by the
Securities and Exchange Commission ("SEC"). The offering may be made
only by means of a prospectus supplement and the accompanying
prospectus, copies of which may be obtained by sending a request to:
Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, NY 10020
or via telephone at (800) 542-0970. Sarepta intends to file a final
prospectus supplement relating to the offering with the SEC, which
will be available along with the accompanying prospectus filed with
the SEC in connection with the shelf registration, on the SEC's
website at http://www.sec.gov/.  
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities of Sarepta, nor shall
there be any sale of securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction. This press release is being issued pursuant to
and in accordance with Rule 134 under the Securities Act of 1933, as
amended. 
Forward-Looking Statements and Information 
This press release contains statements that are forward-looking,
including the statements about the proposed public offering of
Sarepta's common stock, within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. These forward-looking statements involve risks and
uncertainties, many of which are beyond Sarepta's control, including
risk and uncertainties related to market conditions and satisfaction
of customary closing conditions related to the public offering. There
can be no assurance that Sarepta will be able to complete the public
offering on the anticipated terms, or at all. Risks and uncertainties
relating to Sarepta and its business can be found in the "Risk
Factors" section of Sarepta's most recent filing on Form 10-K, Form
10-Q and other SEC filings. Any forward-looking statement in this
press release represents Sarepta's views only as of the date of this
press release and should not be relied upon as representing its views
as of any subsequent date. Sarepta does not undertake any obligation
to publicly update its forward-looking statements based on events or
circumstances after the date hereof, except as required by applicable
law. 
Sarepta Investor and Media Contact: 
Erin Cox
425.354.5140
ecox@sareptatherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.